Global Biomarker Technologies Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global biomarker technologies market size reached US$ 35.4 Billion in 2022. Looking forward, the market is expected to reach US$ 75.9 Billion by 2028, exhibiting a growth rate (CAGR) of 13.56% during 2022-2028.

Biomarker technologies are reliable and cost-effective detection tools that rely on genetic biomarkers, such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), for detecting pathogens. These technologies find extensive application in the early diagnosis of different diseases and disorders. They are also utilized in the drug discovery and development processes and the management of nervous system disorders, cardiovascular diseases, infections, immunological and genetic disorders, and cancer. Some of the commonly used biomarker technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS) and immunoassay.

Biomarker Technologies Market Trends

There is currently a considerable rise in the number of individuals who are suffering from cancer and cardiovascular, neurological, and autoimmune diseases across the globe. This, coupled with the escalating demand for early and effective diagnosis, represents one of the key factors positively influencing the market. Apart from this, the rising geriatric population is also contributing to the growth of the market. Moreover, there is an increase in research and development (R&D) funding for drug discovery by governing agencies of numerous countries. This, along with the considerably expanding healthcare infrastructure, especially in developing countries, is propelling the market growth. Furthermore, leading market players are introducing numerous advancements in biomarker technologies that provide accurate patient stratification. They are also developing digital biomarkers that aid in collecting objective, quantifiable, physiological, and behavioral data by using digital devices. These digital biomarkers are also incorporated with artificial intelligence (AI), machine learning (ML) solutions for big data analysis, and integrated decision making. Other major factors, including rising awareness about the early detection of cancer for better treatment, and surging income levels of individuals, are projected to impel the market growth.

Key Market Segmentation

This research provides an analysis of the key trends in each sub-segment of the global biomarker technologies market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on test type, indication, product, technology and application.

Breakup by Test Type:

• Solid Biopsy
• Liquid Biopsy

Breakup by Indication:

• Cancer
• Infectious Diseases
• Autoimmune Disorders
• Cardiovascular Disorders

Breakup by Product:

• Consumables
• Assay
• Reagent
• Instruments

Breakup by Technology:

• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Immunoassay

Breakup by Application:

• Drug Discovery
• Clinical Diagnostics
• Personalized Medicine

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Latin America
• Brazil
• Mexico
• Middle East and Africa

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., LI-COR Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N.V., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation.

Key Questions Answered in This Report:

• How has the global biomarker technologies market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global biomarker technologies market?
• What are the key regional markets?
• What is the breakup of the market based on the test type?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global biomarker technologies market and who are the key players?
• What is the degree of competition in the industry?